Vontobel Holding Ltd. Makes New Investment in Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Vontobel Holding Ltd. bought a new stake in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 25,000 shares of the company’s stock, valued at approximately $32,000.

Other large investors also recently modified their holdings of the company. Barclays PLC increased its holdings in Actinium Pharmaceuticals by 323.0% in the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after purchasing an additional 32,784 shares during the period. Geode Capital Management LLC lifted its holdings in Actinium Pharmaceuticals by 3.0% in the third quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after buying an additional 19,843 shares during the period. XTX Topco Ltd acquired a new stake in Actinium Pharmaceuticals during the third quarter worth approximately $268,000. Wellington Management Group LLP bought a new stake in shares of Actinium Pharmaceuticals in the 3rd quarter valued at $112,000. Finally, Los Angeles Capital Management LLC bought a new position in Actinium Pharmaceuticals during the third quarter worth $322,000. 27.50% of the stock is currently owned by institutional investors.

Actinium Pharmaceuticals Stock Down 4.9 %

Shares of ATNM opened at $1.17 on Friday. The stock has a market capitalization of $36.50 million, a P/E ratio of -0.84 and a beta of 0.13. The firm has a fifty day simple moving average of $1.24 and a two-hundred day simple moving average of $1.57. Actinium Pharmaceuticals, Inc. has a twelve month low of $1.07 and a twelve month high of $10.24.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ATNM shares. StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Stephens reiterated an “overweight” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a report on Tuesday, November 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Actinium Pharmaceuticals in a research report on Friday, November 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.40.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).